Optimizing Treatment Strategies for Metastatic NSCLC: Achieving the Best Patient Outcomes 

home / meeting-of-the-minds / optimizing-treatment-strategies-for-metastatic-nsclc-achieving-the-best-patient-outcomes

The video series, Optimizing Treatment Strategies for Metastatic NSCLC: Achieving the Best Patient Outcomes, provides expert insights on patient selection, treatment sequencing, and managing adverse events to improve care for EGFR+ and ALK+ metastatic NSCLC patients.

Robert’s Journey With EGFR+ Metastatic NSCLC

EP. 1: Robert’s Journey With EGFR+ Metastatic NSCLC

December 23rd 2024

Profiling a 58-year-old retired construction manager with Stage IV EGFR+ NSCLC, discussing his transition from osimertinib to amivantamab plus chemotherapy, managing side effects, and maintaining hope throughout his treatment journey.

Patient Guidance and Education of EGFR Inhibitor Therapies

EP. 2: Patient Guidance and Education of EGFR Inhibitor Therapies

December 23rd 2024

Medical experts discuss strategies for educating patients on managing side effects of osimertinib and other EGFR inhibitors, with guidance on recognizing symptoms that warrant contacting their care team.

Strategies to Managing Cardiotoxic AEs with Osimertinib

EP. 3: Strategies to Managing Cardiotoxic AEs with Osimertinib

January 29th 2025

Strategies for managing cardiotoxicity in patients on osimertinib are discussed, focusing on monitoring adverse events and balancing symptom management with maintaining treatment efficacy.

Balancing Treatment Benefits and Toxicity: Managing Quality of Life in EGFR+ NSCLC Patients

EP. 4: Balancing Treatment Benefits and Toxicity: Managing Quality of Life in EGFR+ NSCLC Patients

January 29th 2025

Key opinion leaders examine approaches to managing skin-related side effects, such as rash, in patients on EGFR inhibitors, highlighting strategies to address quality-of-life impacts while maintaining the benefits of treatment.